You are here: Industry Insights > biosimilars

News List

Current Situation of Biosimilars in China II: 2016-2020 will be the Prime Time of Biosimilars Tang
December 27, 2017
The Chinese biosimilar market can reach RMB 20-30 billion in 2020...
US regulators approve Pfizer’s Remicade biosimilar pharmatimes
December 18, 2017
The US Food and Drug Administration has issued a green light for Pfizer’s biosimilar of Janssen’s mega blockbuster Remicade.
Ogivri approved as the first biosimilar against certain breast and stomach cancers europeanpharmaceuticalreview
December 05, 2017
The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene…
EU nod for first Herceptin biosimilar pharmatimes
November 21, 2017
European regulators have approved the first biosimilar of Roche’s blockbuster biologic Herceptin, issuing a green light for Samsung Bioepis’ Ontruzant.
Mylan seeks EMA approval for two biosimilars expressbpd
November 08, 2017
Mylan has serious concerns about Teva’s ability to integrate and efficiently run a combined company, and deliver meaningful shareholder value, he said, adding “there is simply no track record for investors to find”. (Reuters)
CPhI Worldwide predicts intense innovator-biogeneric company battle over next 3 years pharmaasia
November 02, 2017
Experts at CPhI say that pharmaceutical regulation will shift due to increased data dependence, and regulatory oversight is slowing six sigma adoption.
Amgen and Simcere partner to develop and commercialise biosimilars in China pharmaceufical-technology
September 29, 2017
US-based biotechnology company Amgen has entered an exclusive agreement with Chinese firm Simcere Pharmaceutical Group to co-develop and commercialise four biosimilars in China.
Amgen, Simcere to Co-Develop and Commercialize Biosimilars in China americanpharmaceuticacreview
September 28, 2017
Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China.
Simcere, Amgen to bring in 4 biosimilars to China biospectrumasia
September 28, 2017
Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars. Simcere will be responsible for distribution and commercialization in China
New study offers detailed insights on biosimilars, follow-on biologics market pharmaasia
August 25, 2017
Biosimilar market is expected to gain prominence due to leading biologic drugs expected to lose exclusivity over the next seven years.

Previous page 1 2 3 4 5 6 Next page